Phase I Study of Bevacizumab, Everolimus, and Panobinostat (LBH-589) in Advanced Solid Tumors

PURPOSE: To define the maximum tolerated dose, clinical toxicities, and pharmacodynamics of bevacizumab, everolimus and panobinostat (LBH-589) when administered in combination in patients with advanced solid tumor malignancies. EXPERIMENT DESIGN: Subjects received 10 mg of panobinostat three times w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Strickler, John H., Starodub, Alexander N., Jia, Jingquan, Meadows, Kellen L., Nixon, Andrew B., Dellinger, Andrew, Morse, Michael A., Uronis, Hope E., Marcom, P. Kelly, Zafar, S. Yousuf, Haley, Sherri T., Hurwitz, Herbert I.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3793400/
https://ncbi.nlm.nih.gov/pubmed/22744359
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-012-1911-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados